S&P 500

5.321,41

0,25%

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

GLPG

Galapagos (GLPG)

Galapagos

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:GLPG

1 2 3 4 5 6 7 8 9 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
22/02/2024	22h01	UK Regulatory	Galapagos announces full year 2023 results and outlook for 2024	LSE:GLPG	Galapagos
15/02/2024	22h01	UK Regulatory	Galapagos presents at EBMT-EHA annual meeting 2024	LSE:GLPG	Galapagos
31/01/2024	22h01	UK Regulatory	Galapagos completes transaction to transfer Jyseleca® business to Alfasigma	LSE:GLPG	Galapagos
06/05/2015	07h31	GlobeNewswire	Galapagos listed 10 years on Euronext Amsterdam and Brussels	LSE:GLPG	Galapagos
06/05/2015	07h31	GlobeNewswire	Galapagos announces launch of proposed global offering	LSE:GLPG	Galapagos
01/05/2015	18h00	GlobeNewswire	BNP Paribas notify of 4.8% shareholding in Galapagos	LSE:GLPG	Galapagos
01/05/2015	18h00	GlobeNewswire	Galapagos creates new warrant plan	LSE:GLPG	Galapagos
27/04/2015	22h00	GlobeNewswire	Filgotinib as monotherapy also hits primary endpoint in DARWIN 2 trial	LSE:GLPG	Galapagos
15/04/2015	23h00	GlobeNewswire	Galapagos files registration statement in the United States for a proposed global offering	LSE:GLPG	Galapagos
14/04/2015	22h00	GlobeNewswire	Galapagos' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in...	LSE:GLPG	Galapagos
27/03/2015	19h29	GlobeNewswire	Publication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015	LSE:GLPG	Galapagos
27/03/2015	07h30	GlobeNewswire	Galapagos raises €5.8 million through warrant exercises, Board and Executive Committee members invest	LSE:GLPG	Galapagos
17/03/2015	07h31	GlobeNewswire	Galapagos regains rights to GLPG1690, announces end of alliance with Janssen	LSE:GLPG	Galapagos
06/03/2015	07h35	GlobeNewswire	Galapagos to be included in Amsterdam Midcap Index	LSE:GLPG	Galapagos
06/03/2015	07h31	GlobeNewswire	Galapagos reports 2014 financial results	LSE:GLPG	Galapagos
23/02/2015	07h30	GlobeNewswire	Galapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatment	LSE:GLPG	Galapagos
16/02/2015	07h30	GlobeNewswire	Galapagos reports positive Phase 1 results for GLPG1690	LSE:GLPG	Galapagos
11/02/2015	07h31	GlobeNewswire	Galapagos receives €1.6 million IWT grant for hepatitis B program	LSE:GLPG	Galapagos
09/02/2015	07h31	GlobeNewswire	BNP Paribas notify of 5.08% shareholding in Galapagos	LSE:GLPG	Galapagos
22/01/2015	07h31	GlobeNewswire	Galapagos receives €2.5 million IWT grant for antibiotic research	LSE:GLPG	Galapagos
21/01/2015	18h56	GlobeNewswire	Delta Lloyd notify of 4.96% shareholding in Galapagos	LSE:GLPG	Galapagos
09/01/2015	07h30	GlobeNewswire	Vicki Sato resigns from Galapagos Board	LSE:GLPG	Galapagos
08/01/2015	07h30	GlobeNewswire	Galapagos starts Phase 2 trial with GLPG1205 in ulcerative colitis patients	LSE:GLPG	Galapagos
19/12/2014	07h31	GlobeNewswire	Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie	LSE:GLPG	Galapagos
16/12/2014	07h32	GlobeNewswire	Galapagos regains full rights to GPR84 inhibitor GLPG1205	LSE:GLPG	Galapagos
12/12/2014	07h31	GlobeNewswire	Galapagos selects second component of its investigational cystic fibrosis combination treatment	LSE:GLPG	Galapagos
08/08/2014	07h30	GlobeNewswire	Galapagos cash position of €232 M provides solid basis for R&D pipeline investment	LSE:GLPG	Galapagos
05/08/2014	07h31	GlobeNewswire	Galapagos receives milestone in osteoarthritis alliance with Servier	LSE:GLPG	Galapagos
25/07/2014	18h00	GlobeNewswire	Galapagos creates new warrant plan	LSE:GLPG	Galapagos
23/07/2014	07h30	GlobeNewswire	MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development	LSE:GLPG	Galapagos